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The advancements in our understanding of the inflammatory and immune mechanisms in rheumatoid arthritis (RA)
have fuelled the development of targeted therapies that block cytokine networks and pathogenic immune cells,
leading to a considerable improvement in the management of RA patients. Nonetheless, no therapy is curative and
clinical remission does not necessarily correspond to non-progression of joint damage. Hence, the biomedical
community has redirected scientific efforts and resources towards the investigation of other biological aspects of the
disease, including the mechanisms driving tissue remodelling and repair. In this regard, stem cell research has attracted
extraordinary attention, with the ultimate goal to develop interventions for the biological repair of damaged tissues in
joint disorders, including RA. The recent evidence that mesenchymal stem cells (MSCs) with the ability to differentiate
into cartilage are present in joint tissues raises an opportunity for therapeutic interventions via targeting intrinsic repair
mechanisms. Under physiological conditions, MSCs in the joint are believed to contribute to the maintenance and
repair of joint tissues. In RA, however, the repair function of MSCs appears to be repressed by the inflammatory milieu.
In addition to being passive targets, MSCs could interact with the immune system and play an active role in the
perpetuation of arthritis and progression of joint damage. Like MSCs, fibroblast-like synoviocytes (FLSs) are part of the
stroma of the synovial membrane. During RA, FLSs undergo proliferation and contribute to the formation of the
deleterious pannus, which mediates damage to articular cartilage and bone. Both FLSs and MSCs are contained within
the mononuclear cell fraction in vitro, from which they can be culture expanded as plastic-adherent fibroblast-like cells.
An important question to address relates to the relationship between MSCs and FLSs. MSCs and FLSs could be the
same cell type with functional specialisation or represent different functional stages of the same stromal lineage. This
review will discuss the roles of MSCs in RA and will address current knowledge of the relative identity between MSCs
and FLSs. It will also examine the immunomodulatory properties of the MSCs and the potential to harness such
properties for the treatment of RA.Introduction
Extensive investigations of the pathogenetic mechanisms
of inflammation and autoimmunity and the resulting in-
creased understanding of cytokine networks and cellular
players in rheumatoid arthritis (RA) have led to the devel-
opment of agents that block tumour necrosis factor
(TNF)α, interleukin (IL)-1 and IL-6 signalling, or target
pathogenic cells such as B cells and osteoclasts [1,2]. Des-
pite significant therapeutic advances, however, two major
problems remain unresolved: (i) up to 30% of RA patients
fail to respond to treatments [1], and (ii) radiographic pro-
gression of joint damage can occur even when clinicalCorrespondence: c.debari@abdn.ac.uk
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is achieved [3,4]. Mechanisms of joint destruction appear
to be at least in part uncoupled from inflammation [5];
hence, suppression of inflammation may not be sufficient
to stop RA disease progression.
A hallmark of RA joint pathology is chronic inflamma-
tion of the synovium (synovitis), which causes cartilage
and bone erosion via interplay between infiltrating inflam-
matory/immune cells and the resident fibroblast-like syno-
viocytes (FLSs). Once established, the erosions do not
heal, posing considerable risks for joint damage progres-
sion towards secondary osteoarthritis and joint failure.
The synovium is also home to mesenchymal stromal/stem
cells (MSCs) [6-9]. These cells, among other functions, are
thought to maintain tissues in adult life and participate in
repair processes. While both FLSs and MSCs are part ofis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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clear. FLSs and MSCs could be the same cell type with
functional specialisation and diversification according to
their positional information and environmental cues, or
they could represent different functional stages of the
same lineage. This review will cover recent insights into
the roles of MSCs in RA while addressing current know-
ledge of the relative identity between MSCs and FLSs, and
will discuss the potential to harness the immunomodula-
tory properties of MSCs for the treatment of RA.
The stroma of synovium: not a one-fibroblast-fits-all
A key tissue in RA is the synovium, a membrane that lines
the cavity of synovial joints. The synovium lubricates the
joint surfaces and provides nutrients to the articular cartil-
age. It consists of a lining layer of macrophage-like (type
A) synoviocytes and FLSs (type B synoviocytes), and a
sublining of loose connective tissue containing fibroblasts
interspersed between endothelium (with juxtaposed peri-
cytes) of small blood vessels. The fibroblasts appear to be
functionally distinct depending on their location. FLSs in
the synovial lining share with the common fibroblasts
many characteristics, including expression of type IV and
V collagens, vimentin and CD90 (Thy-1). However, they
have distinctive features from other fibroblasts, including
the fibroblasts resident in the synovial sublining whose
main function is thought to be production and remodel-
ling of extracellular matrix [10]. The FLSs in the synovial
lining express uridine diphosphoglucose dehydrogenase to
synthesise hyaluronan, an important constituent of syn-
ovial fluid, and secrete lubricin, another critical protein for
joint lubrication [10]. Furthermore, FLSs express cadherin-
11, an adhesion molecule that plays a key role in homoty-
pic aggregation of FLSs in vitro and in vivo [11,12]. FLSs,
but not dermal fibroblasts, have the ability to reproduce a
lining-like structure in a three-dimensional culture in vitro
with similarity to the synovial lining in vivo [13].
Cadherin-11-deficient mice develop normally but lack a
defined synovial lining. In addition, cadherin-11 null FLSs
fail to develop a lining-like structure in vitro, indicating
that lining layer condensation is an inherent feature of
FLSs that requires cadherin-11 [12]. Thus, FLSs in the lin-
ing are a specialised subgroup of fibroblasts, which can be
recognised for their position and expression of cadherin-
11, and appear to be functionally distinct from the fibro-
blasts in the sublining stroma.
Recent lineage tracing studies in mice have unveiled
that, like articular cartilage, the synovium derives from
the embryonic joint interzone [14,15], a stripe of mesen-
chymal tissue in the developing limbs located at the site
of the prospective joint. The joint interzone consists of
two perichondrium-like chondrogenic layers and one
intermediate narrow band of mesenchymal cells. The
central layer of the interzone undergoes a cavitationprocess with the appearance of small clefts which extend
and coalesce to form the synovial cavity [16]. Cells of
the interzone then give rise to the synovium, as well as
other joint structures, including articular cartilage, me-
nisci and ligaments [14,15]. However, whether every sin-
gle cell in the synovium originates from the joint
interzone is not known. Macrophages and endothelial
cells are unlikely to descend from the joint interzone
and instead are most likely to derive from the bone mar-
row [17]. With regards fibroblasts, we could postulate a
dual origin, with FLSs of the lining being progeny of the
joint interzone and the fibroblasts of the sublining pos-
sibly deriving from the bone marrow or, more generally,
blood-borne fibroblasts. In this regard, third passage
primary FLS cultures established from normal synovial
joints of mice carrying green-fluorescent protein (GFP)-
positive bone marrow comprised approximately 1% of
GFP-positive (bone marrow-derived) fibroblast-like cells
[18]. Distinct origins of the synovial fibroblast popula-
tions may be the basis of functional differences and
would strengthen the notion that the FLSs of the lining
and the fibroblasts of the sublining are distinct cell
types. The modern technologies of lineage tracing will
shed light on the origins of the fibroblasts in the
synovium.
Mesenchymal stem cells in synovium: a new
stromal cell player or an old fibroblast?
MSCs were originally isolated from bone marrow [19].
In 2001, we reported the isolation and characterisation
of multipotent MSCs from the adult human synovium
[6]. MSCs in vitro are fibroblast-like cells capable of
plastic adherence, form colonies derived from single
cells (colony forming unit fibroblasts) and can differenti-
ate into mature cells of mesenchymal lineages such as
osteoblasts and chondrocytes [19-22]. The discovery that
the adult human synovium contains cells that after isola-
tion and culture-expansion display a MSC phenotype
and perform MSC functions inspired the intriguing
speculation that, postnatally, the synovium may function
as a reservoir of stem cells for the regeneration or repair
of joint tissues such as the articular cartilage, which have
limited intrinsic repair potential [16]. Of note, in a com-
parative study of MSCs from multiple tissue sources, in-
cluding bone marrow, the synovial MSCs were superior
in cartilage formation [23], suggesting that they may be
the 'natural' chondroprogenitors for articular cartilage
repair.
Following enzymatic release from the synovium, MSCs
and FLSs are both contained within the plastic-adherent
mononuclear cell fraction in vitro, from which they can
be culture-expanded as fibroblast-like cells. Cultures of
FLSs and MSCs are therefore indistinguishable, and at
present no markers permit selective identification of
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cell populations. It is not known, therefore, whether FLS
and MSC properties reside in the same individual cell or
in distinct cell types.
To shed light on the relationship between these two
cell types, we carried out studies at the single cell level.
Culture-expanded synovial clonal cell populations from
normal or osteoarthritic donors displayed a phenotype
compatible with conventional bone marrow MSCs [24].
However, markers alone would not be sufficient to rule
out the presence of FLSs or fibroblasts in general, as cul-
ture conditions are known to affect cell phenotype. All
the 21 synovial cell clones obtained and tested from six
donors were capable of chondrogenic and osteogenic
differentiation, while only 30% of the clones were adipo-
genic [24]. Since all clones displayed mesenchymal dif-
ferentiation potency, one could argue that the MSC
property would be inherent to each plastic-adherent cell,
at least after in vitro culture expansion. However, the ex-
tensive culture expansion required to perform all the ne-
cessary tests to investigate the mesenchymal potency may
have selected for MSC clones, while FLSs or other fibro-
blasts were left behind. In addition, primary fibroblasts de-
rived from various human tissues, including skin, were
reported to contain cells that were able to differentiate
into osteoblasts, chondrocytes and adipocytes [25].
Primary cultures of plastic-adherent cells from RA syno-
vium (commonly regarded as FLSs) have been shown to
contain cells with the functional ability, typical of RA
FLSs, to erode cartilage through matrix metalloproteinases
[17,26], as well as cells with the typical mesenchymal mul-
tipotency of MSCs [27,28]. The relationship between
MSCs and FLSs in the synovial cell pool in vitro is yet to
be clarified, and studies using single cell-derived clonal
populations will be needed to determine whether FLS in-
vasiveness and MSC differentiation potency are inherent
in individual cells from the RA synovium.
Recently, we reported the in vivo identification and lo-
cation of MSCs in mouse synovium [29]. We developed
a double-nucleoside analogue labelling method to iden-
tify functional MSCs in situ in the knee joints of mice
[29] to overcome the hurdle of a lack of MSC-specific
markers. Our labelling approach relied on the slow-
cycling nature of MSCs combined with their propensity
to undergo proliferation following joint surface injury.
Nucleoside-labelled cells were non-haematopoietic, non-
endothelial stromal cells which expressed known MSC
markers and formed ectopic cartilage following joint sur-
face injury and patellar dislocation [29], thereby demon-
strating that these cells have the ability to function as
MSCs in their native environment.
In synovium, MSCs are located mainly in two niches
(Figure 1): the lining niche and the sublining perivascu-
lar niche, the latter distinct from pericytes [29]. In thesetwo niches, MSCs could have distinct functions and still
be geographically interchangeable, but a temporo-spatial
hierarchy between the two MSC niches remains to be
investigated. Furthermore, MSCs in synovium are het-
erogeneous in their phenotype, and this could possibly
reflect a coexistence of functionally distinct cell subsets
[29]. At present, the developmental origins of MSCs in
the adult synovium are not known. They could derive
from the embryonic joint interzone but a contribution
from blood-borne circulating MSCs into the synovial
pool would not be surprising given that MSCs can be
found in the circulation [30] and are likely to traffic
across, home to and engraft in tissues and organs of the
entire body. Origins may differ for MSCs found at dis-
tinct niche sites. The ontogeny of MSCs in synovium
and their maintenance throughout life via possible con-
tribution from other tissues such as bone marrow is an
exciting area of investigation.
Meanwhile, the relationship between the MSCs and
the FLSs in the lining layer remains unclear. In our study
[29], label-retaining (slow-cycling) cells were positive for
the MSC markers PDGFRα, p75/LNGFR, and CD44.
However, CD44 is also known to be expressed by FLSs
[31], and label-retaining cells in the lining layer co-
stained for cadherin-11 [29], a known marker of FLSs
[12]. MSCs in the lining could be 'professional' stem
cells, interspersed in between the FLSs and the macro-
phages. Alternatively, the FLSs could be a stage of differ-
entiation of the MSC lineage, attaining FLS-specific
properties but perhaps remaining able to function as
'non-professional' MSCs under challenging circumstances,
including joint injury or inflammation in vivo, or after iso-
lation and culture expansion in vitro. The existence of cell
plasticity and dedifferentiation has long been controver-
sial, but the induced pluripotent cell technology [32] has
provided 'extreme' proof-of-concept under specific ex-
perimental conditions. If such plasticity were to exist
in vivo, it could allow cells to swing between the perhaps
imprinted embryonic memories of MSCs and the tissue-
specific, functionally specialised cells like the FLSs.
Mesenchymal stem cells: good or bad in
rheumatoid arthritis?
Our current knowledge of the roles of MSCs in RA is lim-
ited. MSCs appear to be passive targets of the inflamma-
tory process but they could also play an active pathogenic
role. While under homeostatic conditions the synovium
contributes to joint maintenance, in RA this tissue exerts a
deleterious, damaging action on the joint, and the FLSs are
known to be major pathogenic cell players. During RA, the
synovium forms a 'pannus' that invades and erodes cartil-
age and bone. The pannus is a pathological outgrowth of
synovial tissue sustained mainly by proliferation of FLSs,
with infiltration of blood-borne inflammatory/immune
Figure 1 Schematic representations of mesenchymal stem cells (MSCs) and their niches in synovium identified in mice using a double-nucleoside
analogue cell-labelling scheme [29]. (A) Schematic drawing of an uninjured control synovial joint. (B) Details of the dashed box in (A), showing cell
populations in the synovium of uninjured joints. Iododeoxyuridine (IdU)-retaining cells (green) were located in both the synovial lining (SL) and the
subsynovial tissue (SST). Subsets of IdU-positive cells displayed an MSC phenotype. IdU-negative cells (blue) included haematopoietic lineage cells (HC),
endothelial cells (EC), pericytes (PC), and other cell types of unknown phenotype. (C) Schematic drawing of a synovial joint 12 days after articular
cartilage injury in mice (arrowhead). (D) Details of the dashed box in (C), showing cell populations in the synovium. Proliferating cells were detected in
both the synovial lining and the subsynovial tissue and were either double positive for IdU and chlorodeoxyuridine (CIdU; orange) or single positive for
CIdU (red). Subsets of cells positive for IdU and CIdU and cells positive only for IdU (green) expressed chondrocyte lineage markers. The boxed areas in (B)
and (D) show cell phenotypes. B, bone; C, cartilage; SC, synovial cavity; SM, synovial membrane. Reproduced from Kurth et al., Arthritis Rheum 2011 [29].
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mesenchymal cells from bone marrow into synovium.
In this regard, primary FLS cultures established from
RA-like arthritic joints of mice carrying GFP-positive
bone marrow contained over 30% of GFP-positive (bone
marrow-derived) cells, significantly higher than the ap-
proximately 1% observed in FLS cultures obtained from
normal joints [18]. The molecular mechanisms underpin-
ning such inflow of mesenchymal cells from bone marrow
into synovium during inflammatory synovitis are not fully
known but chemokines would likely play a role [33]. Re-
cent work has demonstrated that placental growth factor,
whose levels are increased in RA joints, could recruit bone
marrow MSCs to the synovium, where the interactions
with the resident FLSs would contribute to angiogenesis
and chronic synovitis by enhancing further the secretion
of placental growth factor [34].
The erosive changes that occur in association with the
inflammatory synovitis in RA indicate prevalence of car-
tilage/bone loss over repair. FLSs are well known to pro-
duce inflammatory cytokines and to develop an invasive
phenotype with release of proteases that cause cartilage
and bone destruction [35]. At the same time, remodel-
ling/reparative responses appear to be suppressed prob-
ably by the persistent inflammation. The prevalence ofMSCs, as characterised by in vitro multilineage potential,
was significantly lower in the synovial fluid of RA pa-
tients than osteoarthritis patients [36]. In addition, there
was a negative relationship between synovial MSC chon-
drogenic and clonogenic capacities and the magnitude of
synovitis in RA [28], suggesting a suppression of MSC
repair function within the joint perhaps secondary to the
high levels of inflammatory cytokines during RA. TNFα
is indeed known to prevent the mesenchymal differenti-
ation capabilities of MSCs in vitro [37,38]. Thus, in
addition to the well-known catabolic effects of TNFα on
articular cartilage and bone [1], TNFα signalling would
decrease the reparative responses of endogenous joint
MSCs, thereby limiting cartilage/bone regeneration dur-
ing arthritis. Clinical studies in patients with RA indicate
that targeting TNFα can result in inhibition of progres-
sion of structural joint damage [39].
In addition to being 'innocent bystanders' repressed in
their stem cell function by the inflammatory milieu,
MSCs in the joint could be active players contributing to
the pathogenesis of arthritis. Inflammatory cytokines
such as interferon (IFN)-γ are required in vitro to induce
the immunosuppressive and anti-inflammatory functions
in cultured MSCs [40], but whether MSCs in their native
tissues in vivo exert such functions remains unknown.
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eased' MSCs with a differentiation arrested at early stages,
thereby becoming pathogenic cells actively contributing to
RA chronicity and progression. A major downstream tar-
get of inflammatory cytokines is the transcription factor
nuclear factor-κB, and its sustained activation in FLS/MSC
cultures was sufficient to inhibit osteogenic and adipogenic
differentiation and at the same time to enhance prolifera-
tion, motility, and matrix-degrading activity [12]. These
findings would support the 'transformation hypothesis'
that proposes that FLSs/MSCs become transformed by the
chronic interplay with the inflammatory processes in the
joint, resulting in a more aggressive cell type with the abil-
ity to invade the articular cartilage, as demonstrated in
models of co-implantation of normal cartilage and RA
FLSs in vivo in mice [26]. Notably, RA FLSs can circulate
and spread arthritis to unaffected joints [41]. Thus, mesen-
chymal/stromal cell populations could contribute to initi-
ation, maintenance and progression of arthritis, and would
provide recruitment/retention and exit signals to other cell
types, including immune cells [42].
Culture-expanded mesenchymal stem cells as
immunomodulatory therapy for rheumatoid arthritis
Alongside their stem cell properties, culture-expanded
MSCs possess immunomodulatory properties. Studies
predominantly using bone marrow-derived MSCs have
demonstrated that MSC-mediated immunomodulation is
dependent on IFN-γ [43], and is largely mediated by fac-
tors such as indoleamine 2,3-dioxygenase or nitric oxideFigure 2 Possible effects of mesenchymal stem cells (MSCs) on regulatory T
collagen-induced arthritis; IFNγ, interferon-γ; IL-2, interleukin-2; MHC-I, class I m
orphan receptor γt; TGFβ, transforming growth factor β; TNFα, tumour necrossynthase, inhibiting both T- and B-cell proliferation and
function [44]. MSCs can also induce the differentiation of
regulatory T cells and maintain their inhibitory function
[45,46]. Furthermore, MSCs suppress innate immunity
through inhibiting dendritic cell formation and function
[47], decreasing the expression of human leukocyte anti-
gen DR and CD80 and CD86 co-stimulatory molecules on
antigen presenting cells [48], and decreasing the proli-
feration of both resting and IL-2-activated natural killer
cells, their cytotoxic capabilities, and IFN-γ production
[49]. The immunoregulatory properties of cultured syn-
ovial MSCs are less well known but the data available so
far point to similar functions to their bone marrow coun-
terparts [50-53].
The immunosuppressive and anti-inflammatory proper-
ties of cultured MSCs have led to these cells being tested
for their therapeutic potential in preclinical models of RA-
like inflammatory arthritis (reviewed in [40]). Several stud-
ies suggested that bone marrow- or adipose-derived MSCs
have the ability to 'reset' the immune system by reducing
the deleterious Th1/Th17 response and enhancing the
protective regulatory T cell response (Figure 2), although
other studies failed to demonstrate improvement with
MSC treatment [40]. The inconsistent results in pre-
clinical models may be due to several variables such as
source of MSCs (murine syngeneic or allogeneic, or hu-
man), tissue of origin of MSCs, timing of treatment,
number of cells injected, route of injection and treatment
regimes, different culture conditions, as well as differences
in mouse strains and animal housing conditions.cell (Treg) and Th17 cell populations in rheumatoid arthritis (RA). CIA,
ajor histocompatibility complex; RORγt, retinoic acid receptor-related
is factor α. Adapted from MacDonald et al., Arthritis Rheum 2011 [40].
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Intravenous infusion of allogeneic bone marrow or
umbilical cord MSCs into four patients with established
RA resistant to disease-modifying antirheumatic drugs
(DMARDs) and at least one anti-TNFα agent was safe and
resulted in only partial and transient clinical improvement
[54]. More recently, intravenous injection of umbilical cord
MSCs in addition to DMARDs in 136 patients with active
RA who had inadequate responses to traditional medica-
tion induced a significant clinical improvement when com-
pared with the control group of 36 patients who received
DMARDs plus medium without MSCs. The therapeutic
effects were maintained for 3 to 6 months, and correlated
with an increased percentage of regulatory T cells in per-
ipheral blood [55]. Allogeneic MSCs could thus be effect-
ive in RA but a larger multi-centre clinical study will be
needed to provide conclusive evidence. The use of MSCs
in clinical studies is likely to be restricted to patients with
severe RA refractory to standard therapies, but MSC treat-
ment might be more effective if given at early stages of RA
in order to 'reset' the immune system by inducing regula-
tory networks. The selection criteria of RA patients for
such clinical studies will be crucial.
It is tempting to speculate that MSC treatment would
control disease activity in RA patients not only through the
immunosuppressive and anti-inflammatory functions but
also through contribution to joint tissue repair, thereby pre-
venting tissue damage, once established, from continuing to
trigger inflammation. MSC therapeutic approaches to en-
hance joint tissue repair have been trialled in patients with
joint surface defects and/or osteoarthritis with results that
appear promising [56-61], supported by preclinical studies
demonstrating cell engraftment and contribution to tissue
formation leading to meniscal and cartilage repair [62-65].
Thus, the mechanisms through which MSCs can influence
joint disease processes are diverse and include immunosup-
pressive and anti-inflammatory effects, trophic/paracrine
effects and direct contribution to tissue repair. The elucida-
tion of the mechanisms of action of MSC therapies will be
critical to optimise cell product manufacturing for these
positive effects, with the clinical goal of restoration of joint
homeostasis likely to be crucial to halt disease progression.
Immunomodulatory functions of native synovial
fibroblast-like synoviocytes/ mesenchymal stem
cells in joint homeostasis and rheumatoid arthritis
While immune cells have been extensively investigated
in the pathogenesis of RA, little is known about the
in vivo functions of FLSs/MSCs in the regulation of im-
mune homeostasis in physiology and their contribution
to immune deregulation in RA. It is possible that stro-
mal cells in the synovium, particularly FLSs and MSCs,
would be involved in the modulation of immune homeo-
stasis within the healthy joint and that failure of suchimmunomodulation is the basis of RA development.
While FLSs can inhibit T-cell proliferation [66] and the
differentiation of monocytes into dendritic cells [67],
similar to MSCs, RA FLSs have been shown to acquire
class II major histocompatibility complex compared with
healthy FLSs and work as antigen-presenting cells lead-
ing to T-cell activation and proliferation [68]. They can
also induce the activation and accumulation of T cells
following an interaction between CXCR4 on T cells and
its ligand, stromal cell-derived factor-1 on RA FLSs [69].
RA FLSs can increase B-cell recruitment, survival and
functions [70] and induce immunoglobulin class switching
in B cells via B-cell activating factor and a proliferation-
inducing ligand [71]. These findings suggest that within
the RA inflammatory environment, MSCs/FLSs in syno-
vium become unable to control inflammation and instead
contribute to the perpetuation of the inflammation in con-
cert with the aberrant immune system.
Conclusions and future perspectives
Having discussed the multiple facets of MSCs in RA,
from their potential role in the pathogenesis of RA, in-
cluding their relationship with FLSs, to the possibility of
using MSCs as immunomodulators for the treatment of
RA, it becomes apparent that MSCs could be good or
bad depending on the context.
Elucidation of the relationship between MSCs and
FLSs will not only be an important scientific advance-
ment, but will also lay the foundations for devising
tailored therapeutic interventions for RA aiming at stop-
ping the FLSs (bad MSCs) while stimulating the residual
good MSC activity in the joint to achieve repair of dam-
aged tissues such as cartilage and bone and restore joint
homeostasis. The combination of modern research tools
and technologies with pre-clinical mouse models of RA
will be pivotal in addressing whether the FLSs are MSCs
per se (and therefore a subset of the MSC pool) or are
distinct specialised cells, likely down in the MSC lineage
pathway. It will be interesting to determine whether
FLSs/MSCs are descendants of the embryonic joint in-
terzone; FLSs and MSCs could have distinct ancestors.
These are some of the fundamental scientific questions
that we and others are trying to address.
The interplay in vivo between FLSs/MSCs and immune
cells in health and inflammatory arthritis also warrants
further investigation. In normal conditions, FLSs/MSCs
would control the degree of immune responses. Instead,
during RA, due to the inflammatory environmental cues
and the interplay with inflammatory/immune cells, the
immunomodulatory functions of FLSs/MSCs are per-
turbed. FLSs/MSCs then proliferate, leading to the forma-
tion of the deleterious pannus with inflammatory and
aggressive functions, thereby contributing to chronic dis-
ease maintenance and progression. Aberrant crosstalk
Note: This article is part of a thematic series on Biology and
clinical applications of stem cells for autoimmune and
musculoskeletal disorders, edited by Christian Jorgensen and
Anthony Hollander. Other articles in this series can be found at
http://www.biomedcentral.com/series/MSC
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of the vicious cycle underpinning RA chronicity and pro-
gression. An increased understanding of such crosstalk
will be crucial to advance our targeted therapeutic arma-
mentarium for RA patients to stop the vicious cycle sus-
taining chronicity and perhaps even achieve a cure for RA.
The immunosuppressive properties of MSCs are being
exploited for the treatment of RA. It will be important
to identify the RA patient subset most likely to respond
to MSC therapy. Considering the presumed mechanism
of action of MSCs to reset the immune system, an early
intervention could be desirable. If patients receiving
MSC-based therapy are already on conventional therapy
such as DMARDs or biologics, then it will be essential
to determine how these medications will alter MSC
function. Experiments in vitro showed that the addition
of TNFα, a key mediator in RA and one of the main tar-
gets of biological agents [2], reversed the suppressive ef-
fect of MSCs on T-cell proliferation [53,72]. MSC-based
therapy in addition to anti-TNFα therapy could, there-
fore, have a synergistic effect in RA.
Systemically administered MSCs would represent a
source of multipotent stem cells that could be available
for the repair of damaged tissues while exerting their
immunomodulation/suppression. The conflicting results
in studies using MSCs emphasise the need for standar-
dised and robust bioprocessing to obtain consistent and
reliable MSC products. The development of in vitro as-
says of immunomodulatory function predictive of in vivo
clinical outcomes will allow standardisation of MSC
therapy and direct comparison between clinical studies.
Other challenges relate to the biodistribution of the
MSCs and their long-term fate in the body, which re-
main to be fully determined. Genetic engineering of
MSCs for targeted migration to arthritic joints could be
envisaged, for example, by MSCs expressing antibodies
on their cell membrane that recognise epitopes specific
to the damaged articular cartilage [73]. Ultimately, clin-
ical studies will position MSC-based therapeutics in the
treatment algorithm of RA, but this will also comply
with individual patient characteristics, resulting in a per-
sonalised approach (optimal treatment at the right time
in well-defined, stratified patients).
The success of the biologic agents targeting specific cy-
tokines or cell types in the control of the inflammatory
component of RA has made the biomedical community
realise that other aspects of joint biology deserve more
attention, such as the mechanisms driving tissue remo-
delling and repair. Established damage requires repair ap-
proaches and regenerative medicine offers potential for a
lifelong solution. In orthopaedics, cell-based tissue repair
has entered daily clinical practice, and there is anticipation
that the development of injectable regenerative biologics
will soon introduce this practice into rheumatology.Regenerative treatments will find applications for post-
traumatic damaged joints, osteoarthritic and (post)-in-
flammatory joints and will include the repair of damaged
joint surfaces or joint structures such as ligaments and
menisci, or the implantation of off-the-shelf skeletal bio-
structures, such as viable ligaments, menisci and other
joint tissues.
In conclusion, MSC-based therapies via administration
of exogenous MSCs or targeting of the endogenous
MSCs in the joint are strategies that are being pursued
to trigger/enhance repair of the damaged joint tissues,
with the ultimate aim to restore joint homeostasis. With
their wide range of functions, including immunomodu-
latory and anti-inflammatory properties, MSCs offer
ample opportunities for the development of novel treat-
ments for RA. This is an exciting journey in rheumatol-
ogy and we are just at the beginning of it.Abbreviations
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